ETNB 89bio Pharma: Business Value

89bio Pharma - graphic logo of issuer ETNB

89bio, Inc. (ETNB) operates in the NASH segment, where the successful commercialization of a massive market depends on FDA decisions. Due to the lack of certified products, cash flows remain unstable and rely on external financing. This daily price chart on GURU.Markets reflects an Enterprise Value of . Meanwhile, risks are linked to geopolitics, which could block component supplies and disrupt the trial schedule.

ETNB (89bio.com) Total Company Value history from 07/04/2022 to 10/28/2026

89bio, Inc. (ETNB) - metric breakdowns and financial figures

- price and consensus price forecast:
Price 89bio Inc|ETNB - Price Target Chart
- market capitalization data:
Market Capitalization 89bio|ETNB - Enterprise Value
- book capitalization data:
Net Assets per Single Share 89bio|ETNB - Company Book Value|Market Capitalization to Net Assets 89bio.com|ETNB - Company Total Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio 89bio, Inc.|ETNB - Long-Term Debt to Capital|Short-Term Debt to Capital 89bio.com|ETNB - Company Debts|Debt to Net Assets Ratio 89bio|ETNB - Company Long-Term Debt|Company Current Liabilities 89bio
Comprehensive company analysis:89bio Inc (ETNB)
Original product of 89bio, Inc.

Enterprise Value determines the total acquisition cost of a business by summing market capitalization and net debt to eliminate distortions caused solely by the share price. By analyzing the current Enterprise Value, an investor gains insight into the real asset value of 89bio, Inc., which is critical when diversifying developments in metabolic disorder therapies and assessing the company's financial stability prior to entering mass markets.

Competitor analysis for 89bio, Inc.

Ascendis Pharma AS - Aggregate Business Value|Madrigal Pharma (MDGL) - Total Company Value|CORT - Business Value|Rhythm Pharmaceuticals (RYTM) - Enterprise Value|AKRO (akerotx.com) - Total Company Value|Total Company Value Metsera MTSR|Full Business Value MoonLake Immunotherapeutics AG|Crinetics Pharma (CRNX) - Enterprise Value|Value Adjusted for Debt and Cash NewAmsterdam Pharma Corp (NAMS)|Enterprise Value SLNO (Soleno Therapeutics)|amicusrx.com - Enterprise Value|Total Company Value Agios Pharmaceuticals, Inc. (AGIO)|GPCR: Value Adjusted for Debt and Cash|MDXG (MiMedx Group) - Total Company Value|Rezolute Bio (RZLT) - Real Price to Acquire Entire Company|LXRX (Lexicon Pharmaceuticals) - Enterprise Value|Enterprise Value mbxbio.com (MBX)|Altimmune (ALT) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash AARD (Aardvark Therapeutics Inc.)|Sagimet - Total Company Value|Real Price to Acquire Entire Company BioAge Labs, Inc BIOA|BMEA (Biomea Fusion, Inc.) - Enterprise Value|Quince Therapeutics (QNCX) - Total Enterprise Value|GUTS - Real Price to Acquire Entire Company|vTv Therapeutics (VTVT) - Aggregate Business Value|ATPC (Agape ATP Corp) - Enterprise Value|Enterprise Value Pluri Inc|Enterprise Value Synlogic, Inc. (SYBX)|Total Company Value LPCN (lipocine.com)|MTNB: Total Company Value|sprucebiosciences.com - Total Enterprise Value|GLTO - Total Company Value|CTCX - Total Company Value|Lumos Pharma, Inc. - Enterprise Value|ONVO (organovo.com) - Company Buyout Price|RDUS: Total Company Value